(Bloomberg) — The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications. Most Read from Bloomberg Starting April 1, CVS Health Corp. will no longer offer AbbVie Inc.’s Humira to most of the millions of patients in its commercial prescription plans. […]
Person working in pharmacy Drug patents don’t last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings. When it was clear a few years ago that biosimilars for AbbVie‘s (NYSE: ABBV) Humira would be hitting the market, management knew it had work to do. Humira […]